BRPI0620291B8 - método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune - Google Patents

método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune

Info

Publication number
BRPI0620291B8
BRPI0620291B8 BRPI0620291A BRPI0620291A BRPI0620291B8 BR PI0620291 B8 BRPI0620291 B8 BR PI0620291B8 BR PI0620291 A BRPI0620291 A BR PI0620291A BR PI0620291 A BRPI0620291 A BR PI0620291A BR PI0620291 B8 BRPI0620291 B8 BR PI0620291B8
Authority
BR
Brazil
Prior art keywords
immune modulator
bacterial strains
modulator composition
diaminodiphenyl sulfone
roughened
Prior art date
Application number
BRPI0620291A
Other languages
English (en)
Inventor
Ann Stanford Cynthia
Mcintyre Graham
Lawson Stanford John
Adelmo Bottasso Oscar
Original Assignee
Bioeos Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioeos Ltd filed Critical Bioeos Ltd
Publication of BRPI0620291A2 publication Critical patent/BRPI0620291A2/pt
Publication of BRPI0620291B1 publication Critical patent/BRPI0620291B1/pt
Publication of BRPI0620291B8 publication Critical patent/BRPI0620291B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)

Abstract

método de produzir cepas rugosas de bactérias e usos das mesmas a presente invenção refere-se a um método de produzir cepas rugosas de uma bactéria, como mycobacterium obuense, sendo que referido método compreende expor referida bactéria a uma sulfona e/ou sulfonamida (como 4,4'- diaminodifenil sulfona ou um análogo da mesma). uma cepa rugosa de mycobacterium obuense produzível por meio de referido método, e usos da mesma. em particular, usos de uma cepa rugosa de mycobacterium obuense depositada sob o tratado de budapeste na nctc com o número de acesso nctc 13365.
BRPI0620291A 2005-12-21 2006-12-19 método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune BRPI0620291B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526033.6 2005-12-21
GBGB0526033.6A GB0526033D0 (en) 2005-12-21 2005-12-21 Method
PCT/GB2006/004780 WO2007071978A1 (en) 2005-12-21 2006-12-19 Method of producing rough strains of bacteria and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0620291A2 BRPI0620291A2 (pt) 2011-11-08
BRPI0620291B1 BRPI0620291B1 (pt) 2020-12-15
BRPI0620291B8 true BRPI0620291B8 (pt) 2021-05-25

Family

ID=35840894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620291A BRPI0620291B8 (pt) 2005-12-21 2006-12-19 método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune

Country Status (15)

Country Link
US (2) US8071354B2 (pt)
EP (2) EP2298860A3 (pt)
JP (1) JP5202330B2 (pt)
CN (1) CN101384699B (pt)
AT (1) ATE519838T1 (pt)
AU (1) AU2006328209B2 (pt)
BR (1) BRPI0620291B8 (pt)
CA (1) CA2633127C (pt)
DK (1) DK1963484T3 (pt)
ES (1) ES2369569T3 (pt)
GB (1) GB0526033D0 (pt)
NZ (1) NZ568810A (pt)
PL (1) PL1963484T3 (pt)
SI (1) SI1963484T1 (pt)
WO (1) WO2007071978A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
MX2017016931A (es) 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
WO2017143386A1 (en) * 2016-02-25 2017-08-31 Borody Thomas J Compositions and methods of treatment of chronic infectious diseases
BR112018076875A2 (pt) * 2016-06-24 2019-04-02 Aptimmune Biologics, Inc. método de pré-ativação de um sistema imune de sus.
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Preparations containing bacterial strains
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
CN114025794A (zh) * 2018-11-02 2022-02-08 4D制药研究有限公司 包含细菌菌株的组合物
WO2020120717A1 (en) 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising parabacteroides bacterial strains for treating cancer
CN115087729B (zh) * 2020-01-21 2024-06-28 辽宁天安生物制药股份有限公司 赤红球菌细胞壁骨架在再生医学中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054055A (en) 1975-05-27 1979-05-08 Raymond Turcotte Isolation and characterization of phenotypes of mycobacteria
EP0487633A4 (en) 1989-08-17 1993-10-20 Surgical Laser Products, Inc. Integral end structure for medical laser waveguide
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
EP0556284A1 (en) 1990-11-05 1993-08-25 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
US5521300A (en) * 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
ES2158854T3 (es) * 1992-10-13 2001-09-16 Hoffmann La Roche Oligonucleotidos derivados de la familia de genes sod.
US6136529A (en) * 1993-09-03 2000-10-24 Gen-Probe Incorporated Nucleic acid probes to Mycobacterium avium complex
US5786326A (en) * 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
US5994346A (en) * 1995-02-03 1999-11-30 Regents Of The University Of California Use of exochelins in the preservation of organs for transplant
US5721209A (en) * 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
AU710996B2 (en) * 1996-05-22 1999-10-07 Gen-Probe Incorporated Compositions and methods for the detection of mycobacterium kansasii
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9701897D0 (en) * 1997-01-30 1997-03-19 Aqua Health Europ Ltd Vaccine
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
DE19911208A1 (de) * 1999-03-13 2000-09-14 Walther Carl Kurt Gmbh Steckkupplung zur Verbindung von Rohrleitungen, Schläuchen oder dergleichen
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
EP1511753A4 (en) * 2001-09-06 2005-10-12 Activbiotics Inc ANTIMICROBIAL MEDIUM AND ITS USE
WO2003045319A2 (en) * 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364562A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
US7078399B2 (en) * 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
AU2003209127A1 (en) * 2002-02-11 2003-09-04 Auburn University High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
TW200403076A (en) * 2002-06-03 2004-03-01 Activbiotics Inc Intravenous rifalazil formulation and methods of use thereof
SI1534330T1 (sl) 2002-09-06 2014-08-29 Ucl Business Plc Cele bakterijske celice kot imunomodulatorji
US7413728B2 (en) 2003-11-14 2008-08-19 Ucl Biomedica Plc Immune modulator
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
CA2594336A1 (en) * 2004-12-27 2006-07-06 Federal-Mogul Powertrain, Inc. Heat shield for engine mount

Also Published As

Publication number Publication date
EP1963484B1 (en) 2011-08-10
CN101384699B (zh) 2012-10-10
BRPI0620291A2 (pt) 2011-11-08
PL1963484T3 (pl) 2012-08-31
ES2369569T3 (es) 2011-12-02
EP2298860A2 (en) 2011-03-23
WO2007071978A1 (en) 2007-06-28
US8512694B2 (en) 2013-08-20
EP1963484A1 (en) 2008-09-03
EP2298860A3 (en) 2012-04-25
US20090304749A1 (en) 2009-12-10
JP2009520489A (ja) 2009-05-28
CN101384699A (zh) 2009-03-11
JP5202330B2 (ja) 2013-06-05
SI1963484T1 (sl) 2012-06-29
DK1963484T3 (da) 2011-09-19
GB0526033D0 (en) 2006-02-01
CA2633127C (en) 2015-08-04
US20120082699A1 (en) 2012-04-05
ES2369569T8 (es) 2012-06-26
US8071354B2 (en) 2011-12-06
AU2006328209A1 (en) 2007-06-28
BRPI0620291B1 (pt) 2020-12-15
CA2633127A1 (en) 2007-06-28
NZ568810A (en) 2011-09-30
ATE519838T1 (de) 2011-08-15
AU2006328209B2 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
TW200608985A (en) Method and compositions useful for preventing and/or treating sensitive and/or dry skin
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
DE50309853D1 (de) Lineare polyamino- und/oder polyammonium-polysiloxancopolymere ii
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
GB2442201A (en) Method of providing lubricious surfaces
PL2426220T3 (pl) Wyznakowane mikroorganizmy i sposoby wyznakowania
WO2005060707A3 (en) Methods of use of probiotic lactobacilli for companion animals
BRPI0413124A (pt) método e equipamento para melhorar desempenho
WO2005060709A3 (en) Methods of use of probiotic bifidobacteria for companion animals
WO2010011972A8 (en) Teaching reading comprehension
DK1511440T3 (da) Reducering af ansigtsældning og indretning dertil
DK1645626T3 (da) Cellelinie
EP1809661A4 (en) MUTEIN INTERFERON BETA HUMAN
MX2009008580A (es) Composiciones lubricantes personales complementarias y sistema de administracion.
WO2007124917A3 (de) Trainingsgerät
WO2006089161A3 (en) Immunostimulating polyphosphazene compounds
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2006078975A3 (en) Improved vaccine against feline calicivirus
EP1877539A4 (en) MUTANT F. TULARENSIS TRIBE AND USES THEREOF
BRPI0607843A2 (pt) bactéria, composição, uso de metotrexato, e, método para selecionar bactérias tendo níveis de folato intracelular e/ou total aumentados
ATE306977T1 (de) Schaukel für behinderte
BR0215884A (pt) Método para melhorar a função imunológica em mamìferos usando cepas de lactobacillus reuteri
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
WO2008037753A3 (de) Elastische provisorische suprakonstruktion für ein dentales implantat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COPLEMENTAR A RETRIBUICAO DA 4A ANUIDADE DE ACORDO COM A TABELA VIGENTE, REFERENTE A GUIA DE RECOLHIMENTO 221004889024

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE RPI 2320 DE 23/06/2015

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.